A phase 1 dose-escalation and expansion study of binimetinib (MEK162), a potent and selective oral MEK1/2 inhibitor

Johanna C. Bendell, Milind Javle, Tanios S. Bekaii-Saab, Richard S. Finn, Zev A. Wainberg, Daniel A. Laheru, Colin D. Weekes, Benjamin R. Tan, Gazala N. Khan, Mark M. Zalupski, Jeffrey R. Infante, Suzanne Jones, Kyriakos P. Papadopoulos, Anthony W. Tolcher, Renae E. Chavira, Janna L. Christy-Bittel, Emma Barrett, Amita Patnaik